These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1597 related items for PubMed ID: 12853587

  • 21. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.
    Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H.
    N Engl J Med; 1995 Jun 22; 332(25):1661-5. PubMed ID: 7760866
    [Abstract] [Full Text] [Related]

  • 22. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J, Goodin S.
    J Oncol Pharm Pract; 2007 Jun 22; 13(2):85-97. PubMed ID: 17873108
    [Abstract] [Full Text] [Related]

  • 23. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 24. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A.
    Thromb Haemost; 1999 Jan 30; 81(1):26-31. PubMed ID: 9974369
    [Abstract] [Full Text] [Related]

  • 25. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators.
    Br J Surg; 2005 Oct 30; 92(10):1212-20. PubMed ID: 16175516
    [Abstract] [Full Text] [Related]

  • 26. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb 30; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 27. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators.
    N Engl J Med; 2020 Apr 23; 382(17):1599-1607. PubMed ID: 32223112
    [Abstract] [Full Text] [Related]

  • 28. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD, Johnson JA, Turpie AG.
    Arch Intern Med; 2004 Jun 28; 164(12):1319-26. PubMed ID: 15226166
    [Abstract] [Full Text] [Related]

  • 29. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR, Hokusai VTE Cancer Investigators.
    N Engl J Med; 2018 Feb 15; 378(7):615-624. PubMed ID: 29231094
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M.
    Semin Thromb Hemost; 2003 Dec 15; 29 Suppl 1():9-11. PubMed ID: 14730472
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
    Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study.
    N Engl J Med; 2001 Nov 01; 345(18):1305-10. PubMed ID: 11794149
    [Abstract] [Full Text] [Related]

  • 39. Electronic alerts to prevent venous thromboembolism among hospitalized patients.
    Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ.
    N Engl J Med; 2005 Mar 10; 352(10):969-77. PubMed ID: 15758007
    [Abstract] [Full Text] [Related]

  • 40. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
    Goodin S.
    Am J Health Syst Pharm; 2005 Nov 15; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 80.